Carcinoma, Squamous Cell of Head and Neck
Conditions
Brief summary
The purpose of this Phase I/II study is to define the maximum tolerated dose of PD 0332991 given with cetuximab and evaluated the side effects of the combination.
Interventions
BIOLOGICALCetuximab
DRUGPD 0332991
Sponsors
Pfizer
Washington University School of Medicine
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck. * Disease must be considered incurable. Incurable is defined as metastatic disease or a local or regional recurrence in a previously irradiated site that is unresectable (or patient declines resection). * Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥10 mm with CT scan, as ≥20 mm by chest x-ray, or ≥10 mm with calipers by clinical exam. (Phase I only: patients without measurable disease by RECIST 1.1 criteria but with evaluable disease by imaging or physical exam will be eligible as well.) * Phase I only: any (or no) prior therapy for metastatic disease is allowed, including cetuximab. If a patient has not received prior standard therapy, s/he must have been offered and refused prior standard therapy. * Phase II only: * Arm 1: disease progression after at least one cycle of prior treatment with cisplatin or carboplatin for incurable disease. Prior treatment with cetuximab for incurable disease is not permitted. * Arms 2 and 3: disease progression after at least one cycle of treatment with cetuximab for incurable disease. * Phase II only: at least one line of prior therapy for incurable disease. * Phase II only: * Arms1 and 2: disease must be determined to be HPV-unrelated. HPV-unrelated SCCHN is defined as either p16-negative OPSCC or non-OPSCC (larynx, hypopharynx, oral cavity) or p16-negative unknown primary SCC presenting with a level 2 or 3 neck node. p16 will be assessed by IHC; a specimen showing any staining will be considered p16-positive. * Arm 3: disease must be HPV-related SCCHN (defined as OPSCC or unknown primary presenting with a neck mass that is either p16 positive or HPV ISH or PCR positive). * Minimum of 14 days elapsed since the end of any prior therapy. * At least 18 years of age. * Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 4.0 Grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion) * ECOG performance status ≤ 2 * Adequate bone marrow and organ function as defined below: * Absolute neutrophil count ≥ 1,500 mm3 * Platelets ≥ 100,000 mm3 * Hemoglobin \> 9 g/dL * Total bilirubin ≤ 1.5 x IULN except in the case of patients with Gilbert's disease * AST (SGOT) and ALT (SGPT) ≤ 2.5 x IULN for patients without liver metastases and ≤ 5.0 x IULN for patients with liver metastases * Alkaline phosphatase ≤ 2.5 x IULN for patients without bone metastases and ≤ 5.0 x IULN for patients with bone metastases * Serum creatinine ≤ 1.5 x IULN OR calculated creatinine clearance ≥ 50 mL/min/1.73 m2 for patients with creatinine levels above institutional normal * Baseline corrected QT interval (QTc) \< 480 ms. * Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. * Available archival tumor tissue for the proposed correlative studies. * Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion criteria
* Phase II, Arm 1 only: prior treatment with cetuximab. * Resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 4.0 Grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator´s discretion) * A history of other malignancy ≤ 1 year previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only, carcinoma in situ of the cervix, or synchronous H&N primaries. * Currently receiving any other investigational agents. * Patient must not have a history of or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for individuals who have had previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medications (with the exception of Keppra) for 1 month prior to first dose of PD 0332991. * A history of allergic reactions attributed to compounds of similar chemical or biologic composition to PD 0332991, cetuximab, or other agents used in the study. * Treated within the last 7 days prior to Day 1 of protocol therapy with: * Food or drugs that are known to be CYP3A4 inhibitors (e.g. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, clarithromycin, telithromycin, indinavir, ritonavir, nelfinavir, atazanavir, amprenavir, nefazodone, diltiazem, and delavirdine) or inducers (i.e. dexamethasone, glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort). * Drugs that are known to prolong the QT interval. * Drugs that are proton pump inhibitors. * Uncontrolled electrolyte disorders that can compound the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia) * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 28 days of study entry. Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraceptive during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate. * Phase I and Arm 1 of Phase II: Known HIV-positivity and on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with PD 0332991. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated. Arms 2 and 3 of Phase II: patients with HIV infection and antiretroviral therapy are not excluded, as there are no pharmacokinetic tests being performed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase I - Maximum Tolerated Dose (MTD) | 6 months (estimated completion of Phase I) | MTD is the dose level (DL) immediately below the DL at which 2 patients of a cohort experience dose limiting toxicity (DLT) in the 1st cycle (DLTs) Hematologic DLT is any of the below that occur during the 1st cycle that are possibly, probably, or definitely related to the treatment grade 4 neutropenia ≥7 days grade 4 infection with grade 3/4 neutropenia grade 4 thrombocytopenia with life-threatening bleeding treatment held for \>14 days due to hematologic toxicity febrile neutropenia with temperature \>=38.5°C Non-hematologic DLT is any possibly, probably, or definitely related grade 3 or 4 non-hematologic toxicity that occurs during the 1st except for suboptimally treated grade 3 or 4 nausea, vomiting, diarrhea, anorexia, or lymphopenia grade 3 metabolic abnormalities (limited to potassium, magnesium, and calcium) any hypersensitivity/infusion reaction or acneiform rash due to cetuximab treatment held for \>14 days due to non-hematologic toxicity |
| Phase II: Efficacy as Measured by Overall Response Rate | End of treatment (estimated to be 12 months) | Tumor measurements will be collected at baseline, end of every even numbered cycles, and end of treatment. Measured by overall response rate (ORR=CR+PR) defined by RECIST criteria Best overall response is the best response recorded from the start of treatment until disease progression/recurrence Complete Response (CR) is defined as disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase II: Cetuximab Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Up to 30 days following completion of treatment (estimated to be 13 months) | Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 |
| Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Up to 30 days following completion of treatment (estimated to be 13 months) | Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 |
| Phase I: Most Frequent Adverse Events | Up to 30 days following completion of treatment (estimated to be 13 months) | Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 |
| Phase II: Overall Survival (OS) | Up to 5 years | Participants were followed every 2 months for up to 5 years or until death, whichever occurs first. Overall survival is measured from time of diagnosis to time of death. |
| Phase II: Duration of Response | Completion of treatment (estimated to be 12 months) | Duration of overall response is measured from the time measurement criteria are met for CR or PR until the first date that recurrent or progressive disease is objectively documented. |
| Phase II: Progression Free Survival (PFS) | Up to 5 years | Participants were followed every 2 months for up to 5 years or until death, whichever occurs first. PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. |
| Phase II: PD 0332991 Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Up to 30 days following completion of treatment (estimated to be 13 months) | Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Phase I: Dose Level 1 PD 0332991 100 mg per day will be administered on Days 1 through 21 of each 28 day cycle.
Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study. | 3 |
| Phase I: Dose Level 2 PD 0332991 125 mg per day will be administered on Days 1 through 21 of each 28 day cycle.
Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study. | 6 |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN PD 0332991 125 mg per day will be administered on Days 1 through 21 of each 28 day cycle.
Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study. | 31 |
| Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN PD 0332991 125 mg per day will be administered on Days 1 through 21 of each 28 day cycle.
Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study. | 32 |
| Phase II Arm 3: PD 0332991 125 mg per day will be administered on Days 1 through 21 of each 28 day cycle.
Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study. | 24 |
| Total | 96 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Enrolled but did not start treatment | 0 | 0 | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Phase I: Dose Level 1 | Total | Phase II Arm 3: | Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN | Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Dose Level 2 |
|---|---|---|---|---|---|---|
| Age, Continuous | 62 years | 63 years | 66 years | 64 years | 64 years | 61 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 92 Participants | 23 Participants | 30 Participants | 30 Participants | 6 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 16 Participants | 0 Participants | 7 Participants | 7 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 77 Participants | 24 Participants | 24 Participants | 23 Participants | 3 Participants |
| Region of Enrollment United States | 3 participants | 96 participants | 24 participants | 32 participants | 31 participants | 6 participants |
| Sex: Female, Male Female | 0 Participants | 22 Participants | 2 Participants | 11 Participants | 7 Participants | 2 Participants |
| Sex: Female, Male Male | 3 Participants | 74 Participants | 22 Participants | 21 Participants | 24 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 3 | 6 / 6 | 26 / 30 | 19 / 32 | 15 / 24 |
| other Total, other adverse events | 3 / 3 | 6 / 6 | 30 / 30 | 32 / 32 | 24 / 24 |
| serious Total, serious adverse events | 2 / 3 | 4 / 6 | 21 / 30 | 16 / 32 | 9 / 24 |
Outcome results
Primary
Phase II: Efficacy as Measured by Overall Response Rate
Tumor measurements will be collected at baseline, end of every even numbered cycles, and end of treatment. Measured by overall response rate (ORR=CR+PR) defined by RECIST criteria Best overall response is the best response recorded from the start of treatment until disease progression/recurrence Complete Response (CR) is defined as disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters
Time frame: End of treatment (estimated to be 12 months)
Population: Phase I participants were excluded from this outcome measure. 2 participants in Phase II Arm 1 were not evaluable due to early death and inability to measure the target lesion on the post-treatment non-contrast CT scan. 5 participants in Phase II Arm 2 were not evaluable due to comorbidity-related death (N=2), patient withdrawal (N=2), and non-treatment related adverse event (N=1).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN | Phase II: Efficacy as Measured by Overall Response Rate | 11 Participants |
| Phase II Arm 3: | Phase II: Efficacy as Measured by Overall Response Rate | 5 Participants |
| Phase II Arm 3: | Phase II: Efficacy as Measured by Overall Response Rate | 1 Participants |
Primary
Phase I - Maximum Tolerated Dose (MTD)
MTD is the dose level (DL) immediately below the DL at which 2 patients of a cohort experience dose limiting toxicity (DLT) in the 1st cycle (DLTs) Hematologic DLT is any of the below that occur during the 1st cycle that are possibly, probably, or definitely related to the treatment grade 4 neutropenia ≥7 days grade 4 infection with grade 3/4 neutropenia grade 4 thrombocytopenia with life-threatening bleeding treatment held for \>14 days due to hematologic toxicity febrile neutropenia with temperature \>=38.5°C Non-hematologic DLT is any possibly, probably, or definitely related grade 3 or 4 non-hematologic toxicity that occurs during the 1st except for suboptimally treated grade 3 or 4 nausea, vomiting, diarrhea, anorexia, or lymphopenia grade 3 metabolic abnormalities (limited to potassium, magnesium, and calcium) any hypersensitivity/infusion reaction or acneiform rash due to cetuximab treatment held for \>14 days due to non-hematologic toxicity
Time frame: 6 months (estimated completion of Phase I)
Population: Only Phase I participants were evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase I: Dose Level 1 and Dose Level 2 | Phase I - Maximum Tolerated Dose (MTD) | NA mg |
Secondary
Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events
Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Time frame: Up to 30 days following completion of treatment (estimated to be 13 months)
Population: All arms of the Phase II Portion of the study were combined for this outcome measure as the treatment received was the same for each arm.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 fatigue | 48 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 fatigue | 8 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hypoalbuminemia | 37 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hypoalbuminemia | 3 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 anemia | 44 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 anemia | 20 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hyponatremia | 30 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hyponatremia | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hypertension | 24 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hypertension | 3 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 nausea | 30 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 nausea | 3 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 dysphagia | 30 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 dysphagia | 6 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 dyspnea | 29 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 dyspnea | 5 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hypocalcemia | 19 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hypocalcemia | 4 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 lymphocyte count decreased | 19 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 lymphocyte count decreased | 22 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 diarrhea | 21 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 diarrhea | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 AST increased | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 tumor pain | 18 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 tumor pain | 3 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 constipation | 15 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 anorexia | 21 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 anorexia | 3 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 vomiting | 17 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 vomiting | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 dry mouth | 13 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 dry mouth | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 sinus tachycardia | 12 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 sinus tachycardia | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 alkaline phosphatase increased | 12 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 alkaline phosphatase increased | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hypokalemia | 12 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-4 hypokalemia | 11 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hyperglycemia | 11 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hyperglycemia | 11 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hypernatremia | 16 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hypernatremia | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 fever | 12 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 fever | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 dizziness | 9 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 dizziness | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hypercalcemia | 9 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hypercalcemia | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 dry skin | 18 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 dry skin | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 dehydration | 8 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 dehydration | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hypotension | 8 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hypotension | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 creatinine increased | 12 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 creatinine increased | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 trismus | 7 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 trismus | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 elevated INR | 6 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 elevated INR | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 febrile neutropenia | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grade 1-2 abdominal pain | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 abdominal pain | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 colitis | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 colitis | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 tumor hemorrhage | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 tumor hemorrhage | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hematuria | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hematuria | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 duodenal ulcer | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 duodenal ulcer | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 esophageal fistula | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 esophageal fistula | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 oral cavity fistula | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 oral cavity fistula | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 sepsis | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 sepsis | 7 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 duodenal perforation | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 duodenal perforation | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 skin infection | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 skin infection | 4 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 tracheitis | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 tracheitis | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 aspiration | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 catheter-related infection | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 jejunal obstruction | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 weight loss | 24 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 weight loss | 6 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 AST increased | 22 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 constipation | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 cough | 21 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 cough | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 dysarthria | 5 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 dysarthria | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hypophosphatemia | 3 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hypophosphatemia | 8 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 lung infection | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 lung infection | 8 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 febrile neutropenia | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 aspiration | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 pleural effusion | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 pleural effusion | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 pneumothorax | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 pneumothorax | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 catheter-related infection | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 jejunal obstruction | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 mucositis oral | 4 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 mucositis oral | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 oral hemorrhage | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 oral hemorrhage | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grade 5 death, not otherwise specified | 3 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 infusion-related reaction | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 infusion-related reaction | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 urinary tract infection | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 urinary tract infection | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 respiratory failure | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 respiratory failure | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hypothyroidism | 5 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hypothyroidism | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 edema face | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 edema face | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 non-cardiac chest pain | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 non-cardiac chest pain | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 pancreatitis | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 pancreatitis | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 encephalopathy | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 encephalopathy | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 acute kidney injury | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 acute kidney injury | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 proteinuria | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 proteinuria | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 thromboembolic event | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 thromboembolic event | 1 Participants |
Secondary
Phase II: Cetuximab Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events
Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Time frame: Up to 30 days following completion of treatment (estimated to be 13 months)
Population: All arms of the Phase II Portion of the study were combined for this outcome measure as the treatment received was the same for each arm.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Cetuximab Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 acneiform rash | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Cetuximab Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 hypomagnesemia | 23 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Cetuximab Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 hypomagnesemia | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Cetuximab Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 acneiform rash | 60 Participants |
Secondary
Phase II: Duration of Response
Duration of overall response is measured from the time measurement criteria are met for CR or PR until the first date that recurrent or progressive disease is objectively documented.
Time frame: Completion of treatment (estimated to be 12 months)
Population: Phase I participants were not evaluable for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN | Phase II: Duration of Response | 4.0 months |
| Phase II Arm 3: | Phase II: Duration of Response | 6.0 months |
| Phase II Arm 3: | Phase II: Duration of Response | 4.0 months |
Secondary
Phase II: Overall Survival (OS)
Participants were followed every 2 months for up to 5 years or until death, whichever occurs first. Overall survival is measured from time of diagnosis to time of death.
Time frame: Up to 5 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Overall Survival (OS) | 9.75 months |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase II: Overall Survival (OS) | 7.00 months |
| Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN | Phase II: Overall Survival (OS) | 9.32 months |
Secondary
Phase II: PD 0332991 Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events
Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Time frame: Up to 30 days following completion of treatment (estimated to be 13 months)
Population: All arms of the Phase II Portion of the study were combined for this outcome measure as the treatment received was the same for each arm.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: PD 0332991 Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 platelet count decreased | 50 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: PD 0332991 Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 platelet count decreased | 11 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: PD 0332991 Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 neutrophil count decreased | 28 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: PD 0332991 Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 neutrophil count decreased | 29 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: PD 0332991 Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 white blood cell count decreased | 43 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: PD 0332991 Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 white blood cell count decreased | 24 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: PD 0332991 Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 1-2 electrocardiogram QT corrected interval prolonged | 6 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: PD 0332991 Related Adverse Events Occurring in 10% or More of Participants and All Grade 3-5 Adverse Events | Grades 3-5 electrocardiogram QT corrected interval prolonged | 1 Participants |
Secondary
Phase II: Progression Free Survival (PFS)
Participants were followed every 2 months for up to 5 years or until death, whichever occurs first. PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Time frame: Up to 5 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase I: Dose Level 1 and Dose Level 2 | Phase II: Progression Free Survival (PFS) | 5.72 months |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase II: Progression Free Survival (PFS) | 3.75 months |
| Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN | Phase II: Progression Free Survival (PFS) | 1.82 months |
Secondary
Phase I: Most Frequent Adverse Events
Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Time frame: Up to 30 days following completion of treatment (estimated to be 13 months)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 3 Acneiform Rash | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 3 Neutropenia | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grades 1-2 Anemia | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 3 Anemia | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grades 1-2 Thrombocytopenia | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 3 Thrombocytopenia | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grades 1-2 Nausea | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 3 Nausea | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 1-2 Vomiting | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 3 Vomiting | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 1-2 Diarrhea | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 3 Diarrhea | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 1-2 Infusion Reaction | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 3 Infusion Reaction | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 1-2 Acneiform Rash | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 1-2 Hypomagnesemia | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 3 Hypomagnesemia | 1 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grades 1-2 Fatigue | 2 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grade 3 Fatigue | 0 Participants |
| Phase I: Dose Level 1 and Dose Level 2 | Phase I: Most Frequent Adverse Events | Grades 1-2 Neutropenia | 1 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 3 Acneiform Rash | 0 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grades 1-2 Neutropenia | 2 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 1-2 Diarrhea | 1 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 3 Neutropenia | 2 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 3 Thrombocytopenia | 0 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grades 1-2 Anemia | 6 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 3 Diarrhea | 0 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 3 Anemia | 0 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 1-2 Hypomagnesemia | 2 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grades 1-2 Thrombocytopenia | 3 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 1-2 Infusion Reaction | 1 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 3 Fatigue | 0 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grades 1-2 Fatigue | 3 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grades 1-2 Nausea | 2 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 3 Infusion Reaction | 0 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 3 Nausea | 0 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 3 Hypomagnesemia | 0 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 1-2 Vomiting | 1 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 1-2 Acneiform Rash | 5 Participants |
| Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN | Phase I: Most Frequent Adverse Events | Grade 3 Vomiting | 0 Participants |